Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Faze Medicines is a biotechnology company.
Oyster is a clinical stage pharmaceutical company focused on the discovery development & commercialization .
Enwise is a provider of early education for children.
Triplet is developing transformative therapies that treat repeat expansion disorders at their source.
Thrive Market is a membership-based online company that offers natural and organic food products.
Tea Monsters is a robotic tea production workstation.
Rebound Therapeutics is a medical device company.
CardioGard develops a specially designed arterial cannula for the removal of gaseous material during heart bypass surgeries.
Invus has invested in 104 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Invus's top investment sectors include Health Care, Biotechnology, Medical, Medical Device, Chemical. The firm invests across 20 different industry categories.
Among tracked funding rounds, Oyster Point Pharmaceuticals received $120.8M in a Post Ipo Equity round. Invus's total known invested capital is $7.4B.
Invus's average investment size is $80.3M across its portfolio of 104 companies.
Recent Invus portfolio additions include Faze Medicines, Oyster Point Pharmaceuticals, Enwise. These companies were founded in 2020 or later.